Latus Bio Raises $97M to Expand Gene Therapy Pipeline
Latus Bio has closed a $97 million Series A financing round. The significant capital infusion is intended to accelerate the company’s clinical pipeline, specifically targeting...
Get our latest downloads and information first.
Complete the form below to subscribe to our weekly newsletter.
